(Q40831882)

English

Kidney cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1 reference

Europe PubMed Central

Kidney cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

author name string

N J Vogelzang

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

W M Stadler

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

language of work or name

0 references

publication date

1 November 1998

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

352

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

9141

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1691-1696

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumour suppression by the human von Hippel-Lindau gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Full speed ahead for tumor screening

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A Survey on Incidental Renal Cell Carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of papillary renal cell tumours in patients on chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation induced renal cell cancer: a report of 4 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage I renal cell carcinoma. A clinicopathologic study of 82 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The results of radical nephrectomy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Resection of metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine: a phase II study in patients with advanced renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy of metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Irreversible inactivation of interleukin 2 in a pump-based delivery environment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pronephric carcinoma: chromosomes of cells rescued from apoptosis by an oncogenic herpesvirus detected with a polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A new biological framework for cancer research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(98)01041-1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40831882&oldid=1507874969"